Long-acting lipegfilgrastim and antimicrobials as vigorous primary prophylaxis in bendamustine-treated patients with indolent B cell non-Hodgkin lymphoma: a multicentric real-life experience. [PDF]
Support Care CancerGiordano C +11 more
europepmc +1 more source
Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market.
JAMA Netw OpenAbdelaziz A +3 more
europepmc +1 more source
Comparative efficacy and safety of individual short-acting versus long-acting granulocyte colony-stimulating factors, including biosimilars, for primary prophylaxis of chemotherapy-induced myelosuppression in breast cancer patients: a systematic review and network meta-analysis protocol. [PDF]
Front OncolBi X, Shu S, Tang K, Yin P, Chen Y.
europepmc +1 more source
An update from the Pediatric Proton Consortium Registry [PDF]
, 2018 et al,, Perkins, Stephanie M
core +1 more source
Granulocyte colony-stimulating factor-associated aortitis in a man with advanced prostate cancer. [PDF]
IJU Case RepIkadai R, Kitano G, Kato M, Kojima T.
europepmc +1 more source
Literature review analysis of aortitis induced by granulocyte-colony stimulating factor. [PDF]
Front PharmacolZhao T, Xu H.
europepmc +1 more source
Caught in the Crossfire: A Case of Splenic Infarction Amid G-CSF therapy in Chronic Myelomonocytic Leukaemia. [PDF]
Eur J Case Rep Intern MedPeshin S +5 more
europepmc +1 more source
Bridging the preparedness gap: a systematic review of recommended stockpile items for radiological and nuclear emergencies. [PDF]
BMC Emerg MedNocci M +13 more
europepmc +1 more source
What role for real-world evidence in market access of biosimilars? [PDF]
Front PharmacolSimoens S, Lockhart CM, Courmier DF.
europepmc +1 more source
A new STAT3-based potency assay for human G-CSF analog therapeutics. [PDF]
J Pharm Biomed AnalXie T +5 more
europepmc +1 more source